Next Phase Newsletter

A venture capital firm headquartered in Canada likes to be an early-believer and invest in early-stage companies in niche areas that are often overlooked. Interested areas include, but are not limited to, healthcare, food tech, education, clean tech, software and more. The firm only invests in Pre-Seed and Seed stage companies and will typically allocate between $25k-500k USD. The firm has co-led and led rounds, but mainly acts as a co-investor and is open to global companies. 
 
The firm is sector-agnostic and in terms of life science, will invest in devices, health tech, drug discovery, and diagnostics. The firm invests in companies that are pre-phase I and/or in-development. The firm is also indication agnostic. 
 
The firm strongly emphasizes and looks for a dedicated and full-time team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm founded in 2020 and based in the US, is seeking opportunities in the medical devices and digital health sectors of life sciences. The firm is looking to engage in Series A to Series B financing rounds with initial check sizes between 1 – 3 million USD. The firm prefers to lead/co-lead the financing rounds but is open to co-investing. The firm is focused on companies located in North America and Israel. 
 
The firm is interested in early-stage opportunities in medical devices, diagnostics, and digital health sectors but does not invest in therapeutics. The firm is overall opportunistic and will consider various subsectors and indications. For digital health, the firm prefers b-to-b over b-to-c products. The firm will invest in all early-stage companies including pre and post commercial enterprises. 
 
The firm seeks to work with management teams that have prior entrepreneurial experience. The firm prefers to lead financing rounds and will most likely take a board seat when leading. The firm considers themselves an active investor and will work closely with companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

An international family of venture capital funds invests in early-stage, high-growth life science and health technology companies in the US, UK, and Europe. The firm manages both a US and EU based fund. The EU fund primarily provides Series A financing in the range of £2-5M. The EU fund is actively seeking new investment opportunities in the UK and Europe, and the US fund invests in all of US. 
 
The firm is currently seeking to invest in novel early stage biopharma and medical devices opportunities. The firm is opportunistic in terms of subsectors and indications. 
 
The firm requests a board seat in each portfolio company. The firm invests in management teams who are highly driven and tenacious problem solvers.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm with multiple offices in the US partners with and invests in entrepreneurs who are developing breakthrough products leveraging the convergence of biology and/or hardware with advanced computation and AI (referred to as Convergent Tech). The firm employs a multi-stage investment strategy, encompassing both seed and venture investment programs, and assist entrepreneurs with recruiting and customer and supply chain business development. The firm is generally a lead investor, and invests up to $10 million per opportunity; the firm also has an active seed fund that invests smaller amounts at earlier development stages. 
 
The firm is invests in life science start-ups developing advanced materials, process, and device technologies that leverage advanced computational approaches such as deep learning, and unique data generation capabilities. Specific areas of interest include drug discovery platforms, manufacturing platforms, drug delivery platforms, non-invasive diagnostics, and sustainability generally. The firm does not invest in pure-play therapeutic clinical development business models. 
 
The firm favors companies with platform technologies and partnership-based business models. The firm has deep expertise in manufacturing and productization. Additionally, LPs include large pharma and medical device manufacturing companies; the firm helps portfolio companies develop relationships with these strategics. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A leading pharmaceutical company headquartered in China with integrated R&D, manufacturing, marketing, sales and distribution capabilities. The firm operates as a subsidiary of a publicly traded pharmaceutical company. The firm has a strong pipeline in liver diseases, oncology, respiratory diseases and is one of the top pharmaceutical companies in China within these domains. In addition, the firm has strong interest in CNS diseases, metabolic diseases, etc. With extensive experience and successful records of in and out licensing and co-development ventures with oversea companies, the firm is interested in collaborating with oversea companies whose assets align with its current pipeline and areas of interest. The firm is open to a wide range of partnership and capital structures, including co-development, in/out-licensing, equity investments and acquisitions. The firm is interested in opportunities globally. 
 
The firm is interested in therapeutic assets that align with their areas of focus, which include liver diseases, oncology, respiratory disease, CNS disease, metabolic diseases. The firm is open to various modalities within therapeutics, with a particular emphasis on both large and small molecule drugs. The firm seeks assets ranging from pre-clinical to early-clinical stages (Phase I/Phase Ib), but is also open to considering later-stage assets that align well with their scope of interest. 
 
The firm does not have any specific requirement for the company and the management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A Venture Capital firm formed by a partnership between a Europe-based pharma and a US-based VC is currently looking to make seed and venture stage investments into companies ranging anywhere from $200K to $5 million initially and up to $8 million over the life of the investment. The firm is actively seeking investment opportunities throughout the United States and Europe and could make as many as 2-4 new investments over the next year.

The firm is focused on rare and orphan diseases that affect less than 200,000 people throughout the United States. Within this area the firm is open to therapeutics and diagnostics across a number of technology types including, antibodies, small molecules, stem cells, cell therapy, gene therapy, vaccines, molecular diagnostics, and genomics among others. The firm is interested in companies anywhere from pre-clinical through phase III of clinical trials and has no preference for platform or single asset companies. The firm is looking for companies with disease modifying products targeting with significant understanding of the disease pathology. The firm is not interested in biosimilars or generics.

The firm is looking for privately held companies with experienced management teams. The firm looks to act as a hands on investor and seeks board representation following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm founded in 2019 and headquartered in the US invests in early-stage life science companies, typically in Series A, with a focus on companies with smaller capital requirements. Average check size is $8M USD but can range from $1M-15M USD. The firm typically leads rounds but can also participate in syndicates. Though the firm has not invested in a startup abroad, they are open to global opportunities.

The firm is interested in all sectors of life science, but 80% of their interest is drugs. The remaining 20% is focused on other life science verticals such as devices and diagnostics. Areas of interest include orphaned assets, promising data that could potentially be out-licensed but was overlooked, or nutraceutical products that are being developed into drugs. The firm is indication-agnostic, however, gravitates towards and prefers niche areas such as ophthalmology, rare diseases, dermatology, psychiatry, and cardiometabolic diseases. Ideally, the firm would like to fund proof-of-concept data.

The firm requires to take a board seat. The firm does not have strict company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.